Drug Profile

Calcitriol - PUMC Pharmaceutical

Latest Information Update: 31 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PUMC Pharmaceutical Company
Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
Mechanism of Action Vitamin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Feb 2019 No development reported - Phase-III for Secondary hyperparathyroidism in China (IV)
28 Jan 2019 Chemical structure information added
07 Jan 2016 Phase-III clinical trials in Secondary hyperparathyroidism in China (IV) before January 2016

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com